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Abstract 
Assessing the welfare impact of consumer health advisories is a thorny task. Recently, 
Shimshack and Ward (2010) studied how U.S. households responded to FDA’s 2001 
mercury-in-fish advisory. They found that the average at-risk household reduced fish 
consumption by about 24%, resulting in a 21%-reduction in mercury exposure at the 
cost of a 28%-reduction in cardioprotective omega-3 fatty acids. A rough assessment of 
the health costs and benefits led Shimshack and Ward to conclude that the advisory 
policy resulted in an overall consumer welfare loss. In this note, we propose a more 
comprehensive assessment that links the long term cardiovascular health effects of the 
advisory policy to life cycle consumption. In addition to mortality risk, our model 
values the loss in health quality from non-fatal cardiovascular diseases. Using the same 
dose-response relationships as Shimshack and Ward, we find that the expected health 
and mortality loss to the average at-risk household is much larger than they suggested. 
The analysis highlights the importance of accounting for dynamic effects when 
evaluating persistent changes in exposure to environmental health risks.  
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1. Introduction 
Toxicologists use the term hormesis to refer to a substance that is beneficial at low doses but 
harmful at high doses. While the term describes properties of a single substance, it readily applies 
to other indivisible goods such as foods (Hammitt, 2004). Consider the example of dietary fish. 
Most fish are rich in omega-3 fatty acids, which have beneficial effects on cardiovascular health 
(Lee et al., 2009) and on the neurodevelopment of infants (Cohen et al., 2005a). Fish is also the 
primary source of human exposure to mercury (NRC, 2000), which is well known to harm the 
neurodevelopment of infants (Axelrad et al., 2007) and suspected to promote cardiovascular 
diseases in adults (Roman et al., 2011). 
How healthy or harmful fish consumption is depends on the ingested doses of fatty acids and 
mercury. The consumption of moderate amounts of fish provides significant health benefits to 
both adults (Mozaffarian and Rimm, 2006) and infants (Oken et al., 2005). Yet consuming large 
amounts may be detrimental—especially for pregnant women and their unborn offspring 
(Axelrad et al., 2007). In 2001, the U.S. Food and Drug Administration (FDA) issued a mercury-
in-fish advisory to better protect these target consumers. The advisory instructed households with 
pregnant women and young children to reduce fish consumption to no more than 12 oz per week 
and to avoid consumption of some high-in-mercury fish species.  
Recently, Shimshack and Ward (2010, hereafter SW) estimated the substitution effects that 
households made in response to FDA’s mercury-in-fish advisory based on a consumer panel of 
nearly 15,000 U.S. households. They used their empirical estimates of the advisory-induced 
reduction in fish consumption to inform a prominent risk assessment model (Cohen et al., 
2005b). Their tentative benefit-cost assessment suggests that the advisory resulted in a net harm 
to consumers as neurocognitive benefits to children were outweighed by their parents’ larger risk 
of suffering a heart attack or stroke. 
While we endorse SW’s quasi-experimental approach, we believe that their policy 
assessment neglects three important points.  
First, it estimates the effect of reducing fish consumption in adults for only one year. Hence, 
it overlooks the likelihood that women of child-bearing age and other household members who 
reduce fish consumption may continue to consume less fish for several years, perhaps for the rest 
of their lives. The cumulative effects of reducing fish consumption for several years rather than 
one is much larger (Rheinberger and Hammitt, 2012), especially if the reduction continues to 
older ages where the risk of cardiovascular diseases (CVD) increases rapidly.  
Second, it ignores the disutility imposed by non-fatal cardiovascular events, albeit abundant 
empirical evidence suggests that people are willing to pay significant amounts of money to retain 
or improve their health (see Van Houtven et al., 2006 for a recent review). 
Third, the monetary value or willingness-to-pay (WTP) for a persistent change in CVD risk 
depends crucially on the duration of the change and the ages over which it is experienced 
(Hammitt, 2007; Johansson, 2001). 
A comprehensive evaluation of the FDA mercury-in-fish advisory warrants a life cycle 
assessment of the various health effects. Below, we adopt the life cycle consumption model of 
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Murphy and Topel (2006, hereafter MT) to reevaluate the advisory. In a nutshell, our results 
indicate that for a short-term reduction in fish intake the welfare loss of increased CVD mortality 
is close to the loss estimate by SW. However, if the advisory induced people to reduce fish 
consumption for more than a year, health losses would be much larger. Moreover, the expected 
welfare loss associated with reduced quality of life after suffering a non-fatal CVD event is 
estimated to be comparable to the welfare loss associated with reduced life expectancy. We 
conclude that the overall welfare effect of the mercury-in-fish advisory is likely to be even less 
favorable than SW estimated. 
In the remainder of this note, we first discuss how advisory-induced changes in fish 
consumption affect a consumer’s risk profile. We then outline a tractable life cycle consumption 
model and derive the relevant health valuation metrics from this model. Using SW’s empirical 
estimate of the reduction in fish consumption after the implementation of the advisory, we 
present welfare estimates for both fatal and non-fatal CVD risk increments. We close with some 
comments on the valuation of long-term changes in health risks. 
2. Consumer risk profiles 
At-risk households’ consumption responses to FDA’s 2001 mercury-in-fish advisory are clearly 
summarized in SW. In Figure 1, we provide a stylized model of how the reduction in fish intake 
affects the risk profile of a representative consumer. 
Assume that the consumer eats the amount Q0 of fish per year (Panel A). At age a, she takes 
notice of the advisory and, because she is or plans to become pregnant, she reduces fish intake 
from Q0 to Q1. The body concentrations of mercury and fatty acids fall within a few weeks from 
level M0 to M1 and from P0 to P1, respectively (Panel B). The risk of a neurocognitive deficit to 
her offspring decreases as a consequence of the reduced mercury exposure. This beneficial effect 
is partly offset by the reduced intake of fatty acids (unless the consumer takes fish oil 
supplements).1 At the same time, the consumer’s risk of suffering an acute cardiovascular disease 
increases (Panels C and E) as the cardioprotective effect of fatty acids exceeds the cardiovascular 
risk of mercury on average, given the concentrations in dietary fish (Mozaffarian and Rimm, 
2006). 
The dietary change affects both life expectancy and life quality by shifting the survival curve 
from S0 to S1 (Panel D) and the life quality curve from H0 to H1 (Panel F). The size of these shifts 
hinges on the prevalence of acute cardiovascular diseases at all ages t ≥ a, the quantity of fish 
consumed before and after the dietary change, and whether or not the consumer reverts to the pre-
advisory consumption level later in life. 
Economic theory implies that the welfare effect of FDA’s mercury-in-fish advisory can be 
assessed by comparing consumers’ WTP to avoid increments in cardiovascular risk with the 
monetized benefits of reductions in mercury exposure of unborn children (Garber and Phelps, 
1997). The change in mortality risk can be monetized by the consumers’ WTP for risk 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1 SW estimate the adverse effect of reduced fatty acid exposure offsets about two-thirds of the 
beneficial effect of reduced mercury exposure, see their Table 6. 
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reductions, accounting for the time pattern of the risk change (Hammitt, 2007). Similarly, 
increments in the lifetime risk of non-fatal CVDs events can be valued by monetizing the 
expected loss in life quality (Murphy and Topel, 2006). 
Since family food choices usually affect all household members, changes in cardiovascular 
health risk must be aggregated across the members of at-risk households to assess the total health 
effect of the advisory-induced reduction in fish consumption. The sum of these monetized health 
risks can be compared with the monetary value of the effects on unborn children. For a 
household, the net effect depends on the ages over which the mother and other household 
members reduce fish consumption and the number of children born. 
3. Life cycle assessment of changes in cardiovascular risk 
MT’s model builds on earlier life cycle models (Arthur, 1981; Cropper and Sussman, 1990; 
Rosen, 1988; Shepard and Zeckhauser, 1984; Yaari, 1965), all of which presume that a consumer 
of age a seeks to maximize her remaining lifetime expected utility: 
,),())(),(()( )(∫
∞ −−
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atρ dteatStltcutH  (1) 
where ρ is the consumer’s rate of pure time preference. Age-dependent utility derived from 
consumption c(t) and leisure time l(t) is moderated by the quality of the consumer’s health H (t) ≤ 
1 at each age t ≥ a, and the utility of death is normalized to zero (see Rosen, 1988).  
Changes in mortality risk enter the model through the survivor function: 
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where  µ(τ) is the instantaneous mortality rate and S(t, a) denotes the corresponding probability of 
surviving from age a to at least t. A change in mortality affects the survivor function by: 
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with µ0(τ) and µ1(τ) denoting mortality rates before and after the policy intervention.
2 This 
implies that the same health shock (i.e., absolute change in hazard) has a larger impact on life 
expectancy if it occurs earlier in life—no matter whether the shock is temporary or permanent 
(Johannesson et al., 1997). 
Following Yaari (1965), MT assume a perfect capital market in which actuarially fair 
annuities are available so that the discounted value of future consumption equals expected 
wealth. (Cropper and Sussman (1990) extend the model to the case without access to fair 
annuities.) The consumer hence chooses c(t) and l(t) to maximize: 
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2 Eq. (3) is a first-order approximation obtained by differentiating Eq. (2). 
-5- 
where y(t) denotes period-specific income, ρ is the private rate of time preferences, r is the 
market interest rate at which the consumer can borrow or lend, A(a) are initial assets, H(t) is 
exogenous, and λ is the Lagrange multiplier. 
The marginal rate of substitution between the risk of dying in the current year µ(a) and the 
current assets A(a) measures the value per statistical life at age a: 
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The first order condition of the maximization problem in Eq. (4) with respect to wealth is: 
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By inserting Eq. (6) into Eq. (5), the notation can be further simplified to: 
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where )()(/))(),(()( tctyutltcutv c −+ʹ′= is an expression for the age-specific value of a statistical 
life year (Aldy and Viscusi, 2008).3  
By the above formulation the value of remaining lifetime is independent of health quality.4 
This is not to say that improvements in health are worthless, however. The marginal value of 
reducing the risk of a fall in H(t), such as that following a non-fatal heart attack suffered at age a, 
is equal to: 
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where η(a) denotes the age-dependent health decay rate, and h(t) is the expected relative change 
in health quality at any age t ≥ a caused by a change in the risk of a non-fatal health outcome. Vµ 
and Vη are the welfare metrics we will use below to value changes in consumers’ cardiovascular 
health as induced by the reduced fish consumption that SW found in their empirical analysis. 
4. Calibration 
We calibrated the life cycle consumption model assuming Gompertz hazard functions (Leung, 
1994). In a first step, we fitted overall and cardiovascular mortality rates for the U.S. population 
(Table 1) based on current life tables (Arias, 2011) and death statistics (Heron et al., 2009). We 
then took the average reduction in fish consumption among target consumers, ΔQ, as estimated 
by SW and converted it into changes in cardiovascular risk using the same dose–response 
functions as SW (Table 2). The dose-response function assumes that fish consumption affects the 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
3 Here and below, primes indicate first derivatives with respect to the subscript. 
4 This follows because, under the utility function assumed in Eq. (1), both the utility gain from 
survival and the marginal utility cost of spending are proportional to H(t) (Hammitt, 2002).  
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relative risk of CVD; hence the change in absolute risk is proportional to baseline CVD risk, 
which increases with age. The mathematical details of this conversion are given in the Appendix. 
We borrowed MT’s values for v(t), y(t), c(t), and H(t) as summarized in Table 3. Their 
estimates of y(t) and c(t) are based on official statistics on annual income and consumption 
expenditure; v(t) and H(t) are calibrated to y(t) and c(t) using the first-order condition (6) and 
imply a value per statistical life very similar to the one assumed by SW.5 
There are several ways to model the effect of a change in the risk of a non-fatal 
cardiovascular event on life quality. The approach proposed here builds on the idea that a stroke 
or heart attack at any age t ≥ a can be conceptualized as a random binary event to be survived 
with probability π(t). This conditional survival probability can be approximated from age-specific 
incidence and mortality rates of CVD events (Table 1) and enables calculation of the odds of 
surviving a random CVD event. The associated increment in the risk of a non-fatal CVD event, 
∆p(t), is obtained by multiplying the odds ratio and the advisory-induced increment in CVD 
mortality risk.6 
A survived CVD event entails a loss in health quality, which we assume to be permanent and 
estimate based on Medical Expenditure Panel Survey (MEPS) data.7 The 2000-2003 waves of 
MEPS asked participants to rate their overall health quality using the EQ-5D metric (EuroQol 
Group, 1990). We regressed the health quality scores of 32,222 individuals aged 35 to 90 on their 
age, CVD status, and other controls that affect perceived health quality.8 About 7.5% of the 
sample had previously suffered a stroke or heart attack. Fig. 2 displays the reported and predicted 
health quality scores for individuals of different ages who had or had not ever suffered a non-fatal 
CVD event. The health quality scores predicted for individuals with and without CVD yield a 
relative measure of CVD-induced loss in health quality: 
],,0CVD|)(Y[E/],1CVD|)(E[Y1)( XX ==−=Δ tttq  (9) 
where X  denotes the controls evaluated at sample means. Together, ∆q(t) and ∆p(t) define the 
advisory-induced change in the health decay rate: ∆q(t) ∆p(t) = ∆η(t). Once ∆η(t) is known, it is 
straightforward to derive the advisory-induced change in life quality, ( , ) ( )
t
a
t a dη τ τΛ = Δ∫ . The 
relative effect of a change in non-fatal health risk on life quality can then be calculated as: 
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5 This calibration seems appropriate for the comparative purpose of our note, but one could 
choose other values of v(t), y(t), c(t), and H(t). 
6 Formally, the risk of a non-fatal and a fatal CVD event are related through: p(t) = µ(t) π(t)/(1– 
π(t)), or equivalently: Pr(Survive CVD) = Pr(Death | CVD occurs) * Pr(CVD occurs) * Pr(Survive 
CVD | CVD occurs) / Pr(Death | CVD occurs). 
7 MEPS data were retrieved from: http://meps.ahrq.gov/mepsweb. 
8 We included gender, race, body mass index, smoking status, depression status, angina status, 
diabetes status, income status, and medical expenditure in the past year as controls. Details are in 
the Appendix. 
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5. Results 
In Table 4 we report estimated monetary values of the decreased duration and quality of life 
among adult members of the average at-risk household expected from a 24% reduction in fish 
consumption (SW’s central estimate). We consider reduced fish consumption over a period of 
one to ten years, assuming consumers return to their initial consumption level Q0 once they pass 
childbearing age. Note that estimated CVD losses for consumers younger than 35 are assumed to 
be negligible, because their baseline risk is so small (Lloyd-Jones et al., 2010). We also provide 
estimates for a life-long reduction that could occur because eating habits persist. 
Depending on the age at which fish consumption is reduced and the length of the dietary 
change, the expected monetized health loss to the average at-risk consumer varies from $0 to 
$151. Losses in life expectancy and in life quality contribute about equally to the overall health 
loss. Compared to SW’s central loss estimate of $19 for households who reduced but did not 
eliminate fish consumption (see their Table 6), our estimates become much larger as soon as the 
dietary change spans a period longer than a year.9 This is because the expected losses in life 
expectancy and life quality increase with each year of lower fish consumption at an increasing 
rate, as the baseline CVD risk increases with age. Since the proposed life cycle consumption 
model is based on a relative assessment of CVD risk, it is also not surprising that the expected 
health loss from reduced fish consumption increases with the switching age of consumers. 
SW also estimated the share of consumers who stopped eating significant quantities of fish 
after receiving the mercury warning. They estimated that about 8.1% of U.S. consumers reduced 
their fish consumption to less than 100g of fish per month, and that this would increase the risk of 
a heart attack by 17% and the risk of a stroke by 12%. Exploiting the relative nature of the risk 
assessment within the life cycle consumption model, we can simply scale up the estimates 
reported in Table 4 by a factor of 4.2 to assess the health loss of ceasing fish consumption.10 
Again, for dietary changes longer than a year the expected health loss to the average at-risk 
household is much larger than the $72 obtained by SW. 
6. Conclusions 
Assessing the welfare impact of consumer health advisories is a thorny task. In this note, we 
combine SW’s (2010) estimates of the causal effect of the advisory message on American 
households’ fish consumption and MT’s (2006) life cycle consumption model to reevaluate 
FDA’s mercury-in-fish advisory. We find the adverse effects on adult health are likely to have 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
9 SW assumed that the average at-risk household consists of 1.92 adults (of the same age). In 
order to facilitate comparison with their reported estimates, one would have to multiply our 
estimates by a factor 1.92. 
10 The scaling factor [4.2] can be calculated as: Share of ceasing consumers [8.1%] * (Relative 
increment in heart attack risk [17%] + Relative increment in stroke risk [12%])/{Average yearly 
fish consumption [0.49 kg/yr] * (dose-response function for heart attack risk [7.50 E-3 yr/kg] + 
dose-response function for stroke risk [3.85 E-3 yr/kg])}. 
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been substantially larger than assessed by SW, and hence the net welfare effects of the policy to 
be more adverse than they suggested. 
The most important difference between our dynamic analysis and SW’s original analysis is 
that we account for the likelihood that reductions in fish consumption last more than one year. 
SW analyzed the effects of reducing fish consumption for one year on the cognitive effects to 
offspring (assumed to persist over their lifetimes) and the incremental CVD risk from the same 
consumption change to adults. Realistically, women whose behavior is affected by the advisory 
may reduce fish consumption over the period during which they are or may become pregnant. 
After child-bearing, they may or may not revert to their previous fish consumption levels. Other 
household members, notably their spouses, may also reduce fish consumption over the same 
period. The assessment of the net welfare effects of the advisory on parents and offspring 
requires determining the number, ages, and periods over which adults reduce fish consumption, 
and the number of children born who benefit from reduced mercury exposure. 
The effects of a multi-year reduction in fish consumption on CVD risk and the monetary 
value of the risk change could be assessed, to first order, by multiplying the effects of a one year 
change presented by SW. For dietary changes that last more than a few years, however, this 
approximation will be biased, for both CVD risk and valuation (Johansson, 2001). In particular, 
linear extrapolation will significantly understate the increment in CVD risk. This follows because 
lower fish consumption increases the relative risk of CVD and so the absolute risk increase is 
proportional to baseline risk, which rises with age. Hence total CVD risk is a convex function of 
the duration of the reduction in fish consumption. 
The effect on monetary valuation of the risk change is less clear. Risk changes at older ages 
should be valued by an age-specific value per statistical life, which may decrease with age 
(Hammitt, 2007; Johansson, 2002), and should be discounted for latency. Our use of the MT 
(2006) model to value mortality risk implies that the age-specific value per statistical life 
decreases with age because of reduced life expectancy and future health. The value of a constant 
annual risk reduction is therefore a concave function of the number of years over which it is 
experienced. In the current application, the increasing risk change outweighs the decreasing 
valuation so that the monetary value of changes in CVD risk is a convex function of duration of 
the dietary change. 
A second important difference between our analysis and SW’s is that we include the value of 
reduced health quality associated with non-fatal CVD. While conceptually straightforward, 
including the value of morbidity effects appears to be quite important in this case. The estimated 
monetary value of the expected reduction in health quality is comparable to the value of reduced 
longevity, effectively doubling the loss if only mortality is included. 
In sum, welfare assessment for persistent changes in factors that influence risk of fatality or 
chronic disease requires using a dynamic model to account for how changes in risk and valuation 
accumulate over the course of life. The value of a one year change in risk exposure (aka a "blip", 
Johannesson et al., 1997) substantially underestimates the value of a multi-year change. Although 
the value of a multi-year change can be approximated by extrapolating the effects of a short-term 
change in exposure, such an approach may yield significantly biased welfare estimates. 
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Tables 
Table 1: Hazard functions for overall, heart attack, and stroke mortality in the U.S. population. 
Hazard functions a Shape parameter [α] Scale parameter [β] Source 
Overall mortality rate [µ0(t)] 6.535E-5 8.376E-2 (Arias, 2011) 
Heart attack mortality rate [µ h(t)] 3.395E-6 9.272E-2 (Heron et al., 2009) 
Stroke mortality rate [µ s(t)] 1.166E-6 1.050E-1 (Heron et al., 2009) 
CVD incidence rate [ι(t)] 3.045E-4 6.406E-2 (Lloyd-Jones et al., 2010) 
Survival of a CVD event [π(t)] b 2.242E-2 3.176E-2 1 − [µ s(t)/ι(t) + µh(t)/ι(t)] 
Notes: a Gompertz hazard function of the form µ(t) =α exp(β t); b Complementary hazard function 
of the form π(t) = 1 – α exp(β t). 
 
 
Table 2: Dose–response relationships. 
Parameter Value Source 
Heart attack risk dose – response [ψ h] 7.500E-3 per kg/yr (Cohen et al., 2005b) 
Stroke risk dose – response [ψ s] 3.846E-3 per kg/yr (Cohen et al., 2005b) 
Reduced fish intake [ΔQ] a 4.940E-1 kg/yr (Shimshack and Ward, 2010) 
Notes: a Calculation based on the product of the estimated proportional reduction (21.1%) and the 
annual per capita fish consumption (2.334 kg = 5.147 pounds), see the Appendix of SW’s paper. 
 
 
Table 3: Calibration of MT’s life cycle consumption model (Murphy and Topel, 2006). 
Component Functional form 
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Table 4: Monetized losses of life expectancy and life quality among target consumers. 
 Period of the dietary change: 
Starting age: 1 yr 2 yrs 5 yrs 10 yrs Permanent 
Age 30 $0 $0 $0 
$34 
[$14 + $19] 
$1,272 
[$312 + $960] 
Age 35 
$7 
[$3 + $4] 
$15 
[$6 + $9] 
$40 
[$18 + $22] 
$87 
[$40 + $47]	  
$1,479 
[$364 + $1,115] 
Age 40 
$10 
[$5 + $5] 
$21 
[$10 + $11] 
$54 
[$26 + $28] 
$116 
[$58 + $58] 
$1,662 
[$404 + $1,258] 
Age 45 
$14 
[$7 + $7] 
$28 
[$14 + $14] 
$72 
[$38 + $34] 
$151 
[$83 + $68] 
$1,853 
[$443 + $1,410] 
Notes: The first (second) figure in squared brackets is the monetized loss of life expectancy 
(quality) expected from a 24%-reduction in fish consumption by target consumers aged 30 to 45 
at the beginning of the dietary change. The calculation presumes that below the age of 35 CVD 
risk is negligibly small (Llyod-Jones et al., 2010). 
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Figures 
Figure 1: Effects of a dietary change in fish consumption lasting from age a through age t. 
A – Advisory-induced change in average daily intake [Q] 
 
 
B – Advisory-induced change in exposure to MeHg [M] & PUFAs [P] 
 
 
C – Advisory-induced change (aka blip) in mortality rate [µ] 
 
D – Permanent change in life expectancy [S] 
 
E – Advisory-induced change (aka blip) in health decay rate [η] 
 
F – Permanent change in life quality [H] 
 
 
  
-12- 
Figure 2: Reported and predicted health quality scores for individuals of different age.  
 
 
Notes: Figure based on data from the 2000-2003 waves of the Medical Expenditure Survey. The 
red (green) line shows the predicted decay of health quality over the lifetime for individuals who 
had (not) suffered a non-fatal CVD event. 
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Table A1: Mathematical derivation of advisory-induced changes in life expectancy. 
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Table A2: Mathematical derivation of advisory-induced changes in life quality. 
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Table A1: Descriptive statistics of the 2000-2003 MEPS data sample (N = 32,222). 
Variable Mean Std. dev. 5th percentile Median 95th percentile 
Age 53.95 13.67 35 51 80 
Female 0.46 0.50 0 0 1 
Race:  
Black 0.13  0 0 1 
White, Hispanic, and Asian Americans 0.82  0 1 1 
Other races 0.05  0 0 0 
Body mass index a 27.67 5.74 20.2 26.6 38.4 
Smoking status 0.22 0.41 0 0 1 
Depression status 0.29 0.46 0 0 1 
Angina status 0.03 018 0 0 0 
Diabetes status 0.10 0.30 0 0 1 
CVD status 0.08 0.26 0 0 1 
Income class: 
Poor (HHI ≤ 100% of PL) 0.12  0 0 1 
Near poor (HHI 100-125% of PL) 0.05  0 0 0 
Low income (HHI 126-200% of PL) 0.14  0 0 1 
Middle income (HHI 201-400% of PL) 0.30  0 0 1 
High income (HHI > 400% of PL) 0.39  0 0 1 
Medical expenditure in the past year 56.67 327.30 0 0 279.90 
Wave:  
2000 0.16  0 0 1 
2001 0.27  0 0 1 
2002 0.17  0 0 1 
2003 0.40  0 0 1 
Notes: a Body mass data for the 2000 wave had to be constructed from data on weight and height. 
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Table A2: OLS regression of MEPS health quality scores on controls (N = 32,222). 
 Coef. 5%-CI 95%-CI Robust SE Pr(>|t|) 
(Intercept) 81.257 76.565 85.950 2.346 0.000 
Age -0.015 -0.131 0.102 0.058 0.802 
Age : CVD -0.030 -0.118 0.058 0.044 0.501 
Age : CVD : Depression 0.162 0.028 0.295 0.067 0.016 
Age : Depression -0.068 -0.103 -0.034 0.017 0.000 
Age : Male 0.028 0.001 0.055 0.013 0.036 
Age2 -0.002 -0.003 -0.001 0.001 0.002 
BMI 0.369 0.125 0.612 0.122 0.003 
BMI2 -0.011 -0.015 -0.007 0.002 0.000 
CVD -5.384 -11.284 0.517 2.950 0.068 
CVD : Depression -11.817 -20.728 -2.906 4.455 0.008 
Angina -3.762 -5.057 -2.466 0.648 0.000 
Depression -11.404 -13.287 -9.521 0.942 0.000 
Diabetes -5.952 -6.654 -5.250 0.351 0.000 
Smoke -3.410 -3.865 -2.955 0.228 0.000 
Medical expenditure -0.002 -0.002 -0.001 0.000 0.000 
Near poor a 2.852 1.716 3.989 0.568 0.000 
Low income a 4.038 3.220 4.856 0.409 0.000 
Middle income a 6.620 5.901 7.340 0.360 0.000 
High income a 8.507 7.802 9.211 0.352 0.000 
Male -1.824 -3.260 -0.387 0.718 0.011 
Black b -0.244 -0.814 0.326 0.285 0.392 
Other races b -2.620 -3.446 -1.794 0.413 0.000 
Wave 2001 1.799 1.246 2.353 0.277 0.000 
Wave 2002 1.886 1.273 2.499 0.307 0.000 
Wave 2003 2.030 1.497 2.562 0.266 0.000 
R2 0.320 
Residual SE: 15.39 on 32196 degrees of freedom 
F-statistic: 607 on 25 and 32196 DF, p-value: < 2.2e-16 
Notes: a Baseline is poverty line; b baseline are White, Hispanic, or Asian Americans. 
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